Climb Bio, Inc.

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

CLYM$11.74+6.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balances at December 31, 2023	27,626,435	$3	$263,577	$(2)	$(155,979)	$107,599
Vesting of restricted stock awards and units	154,599	—	—	—	—	—
Issuance of common stock upon exercise of stock options	2,676,071	—	10,979	—	—	10,979
Issuance of common stock in private placement, net of issuance cost of $250	31,238,282	3	119,747	—	—	119,750
Issuance of common stock for the acquisition of in-process research and development from a related party	5,560,047	1	41,867	—	—	41,868
Stock-based compensation expense	—	—	5,557	—	—	5,557
Unrealized gain on marketable securities	—	—	—	25	—	25
Net loss	—	—	—	—	(73,897)	(73,897)
Balances at December 31, 2024	67,255,434	7	441,727	23	(229,876)	211,881
Vesting of restricted stock units	929,563	—	—	—	—	—
Issuance of common stock upon exercise of stock options	21,341	—	65	—	—	65
Exchange of common stock for pre-funded warrant, net of issuance costs of $86	(20,440,000)	(2)	(84)	—	—	(86)
Stock-based compensation expense	—	—	8,054	—	—	8,054
Unrealized gain on marketable securities	—	—	—	412	—	412
Net loss	—	—	—	—	(59,851)	(59,851)
Balances at December 31, 2025	47,766,338	$5	$449,762	$435	$(289,727)	$160,475

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.